guest ::
| Home > Publications Database > Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo. > print |
| Home > Publications Database > Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo. > print |
| 001 | 259006 | ||
| 005 | 20240112171451.0 | ||
| 024 | 7 | _ | |a pmc:PMC10334564 |2 pmc |
| 024 | 7 | _ | |a 10.1186/s40478-023-01592-z |2 doi |
| 024 | 7 | _ | |a pmid:37434215 |2 pmid |
| 024 | 7 | _ | |a altmetric:151530998 |2 altmetric |
| 037 | _ | _ | |a DZNE-2023-00715 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Riemenschneider, Henrick |0 P:(DE-2719)2812261 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo. |
| 260 | _ | _ | |a London |c 2023 |b Biomed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1689236909_15885 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Cytoplasmic aggregation and concomitant nuclear clearance of the RNA-binding protein TDP-43 are found in ~ 90% of cases of amyotrophic lateral sclerosis and ~ 45% of patients living with frontotemporal lobar degeneration, but no disease-modifying therapy is available. Antibody therapy targeting other aggregating proteins associated with neurodegenerative disorders has shown beneficial effects in animal models and clinical trials. The most effective epitopes for safe antibody therapy targeting TDP-43 are unknown. Here, we identified safe and effective epitopes in TDP-43 for active and potential future passive immunotherapy. We prescreened 15 peptide antigens covering all regions of TDP-43 to identify the most immunogenic epitopes and to raise novel monoclonal antibodies in wild-type mice. Most peptides induced a considerable antibody response and no antigen triggered obvious side effects. Thus, we immunized mice with rapidly progressing TDP-43 proteinopathy ('rNLS8' model) with the nine most immunogenic peptides in five pools prior to TDP-43ΔNLS transgene induction. Strikingly, combined administration of two N-terminal peptides induced genetic background-specific sudden lethality in several mice and was therefore discontinued. Despite a strong antibody response, no TDP-43 peptide prevented the rapid body weight loss or reduced phospho-TDP-43 levels as well as the profound astrogliosis and microgliosis in rNLS8 mice. However, immunization with a C-terminal peptide containing the disease-associated phospho-serines 409/410 significantly lowered serum neurofilament light chain levels, indicative of reduced neuroaxonal damage. Transcriptomic profiling showed a pronounced neuroinflammatory signature (IL-1β, TNF-α, NfκB) in rNLS8 mice and suggested modest benefits of immunization targeting the glycine-rich region. Several novel monoclonal antibodies targeting the glycine-rich domain potently reduced phase separation and aggregation of TDP-43 in vitro and prevented cellular uptake of preformed aggregates. Our unbiased screen suggests that targeting the RRM2 domain and the C-terminal region of TDP-43 by active or passive immunization may be beneficial in TDP-43 proteinopathies by inhibiting cardinal processes of disease progression. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Antibodies, Monoclonal |2 MeSH |
| 650 | _ | 2 | |a Epitopes |2 MeSH |
| 650 | _ | 2 | |a Immunization |2 MeSH |
| 650 | _ | 2 | |a Intermediate Filaments |2 MeSH |
| 650 | _ | 2 | |a NF-kappa B |2 MeSH |
| 650 | _ | 7 | |a Antibodies, Monoclonal |2 NLM Chemicals |
| 650 | _ | 7 | |a Aggregation |2 Other |
| 650 | _ | 7 | |a Amyotrophic lateral sclerosis |2 Other |
| 650 | _ | 7 | |a Frontotemporal dementia |2 Other |
| 650 | _ | 7 | |a Immunotherapy |2 Other |
| 650 | _ | 7 | |a Neurodegeneration |2 Other |
| 650 | _ | 7 | |a Phase separation |2 Other |
| 650 | _ | 7 | |a TDP-43 |2 Other |
| 650 | _ | 7 | |a Epitopes |2 NLM Chemicals |
| 650 | _ | 7 | |a NF-kappa B |2 NLM Chemicals |
| 650 | _ | 7 | |a TDP-43 protein, mouse |2 NLM Chemicals |
| 700 | 1 | _ | |a Simonetti, Francesca |0 P:(DE-2719)9001596 |b 1 |e First author |u dzne |
| 700 | 1 | _ | |a Sheth, Udit |b 2 |
| 700 | 1 | _ | |a Katona, Eszter |0 P:(DE-2719)9001378 |b 3 |e First author |u dzne |
| 700 | 1 | _ | |a Roth, Stefan |b 4 |
| 700 | 1 | _ | |a Hutten, Saskia |b 5 |
| 700 | 1 | _ | |a Farny, Daniel |0 P:(DE-2719)2812127 |b 6 |u dzne |
| 700 | 1 | _ | |a Michaelsen, Meike |0 P:(DE-2719)2811691 |b 7 |u dzne |
| 700 | 1 | _ | |a Nuscher, Brigitte |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Schmidt, Michael K |b 9 |
| 700 | 1 | _ | |a Flatley, Andrew |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Schepers, Aloys |b 11 |
| 700 | 1 | _ | |a Gruijs da Silva, Lara A |b 12 |
| 700 | 1 | _ | |a Zhou, Qihui |0 P:(DE-2719)2811347 |b 13 |u dzne |
| 700 | 1 | _ | |a Klopstock, Thomas |0 P:(DE-2719)2810704 |b 14 |u dzne |
| 700 | 1 | _ | |a Liesz, Arthur |b 15 |
| 700 | 1 | _ | |a Arzberger, Thomas |0 P:(DE-2719)2811333 |b 16 |u dzne |
| 700 | 1 | _ | |a Herms, Jochen |0 P:(DE-2719)2810441 |b 17 |u dzne |
| 700 | 1 | _ | |a Feederle, Regina |0 P:(DE-2719)2812867 |b 18 |u dzne |
| 700 | 1 | _ | |a Gendron, Tania F |b 19 |
| 700 | 1 | _ | |a Dormann, Dorothee |b 20 |
| 700 | 1 | _ | |a Edbauer, Dieter |0 P:(DE-2719)2231621 |b 21 |e Last author |
| 773 | _ | _ | |a 10.1186/s40478-023-01592-z |g Vol. 11, no. 1, p. 112 |0 PERI:(DE-600)2715589-4 |n 1 |p 112 |t Acta Neuropathologica Communications |v 11 |y 2023 |x 2051-5960 |
| 856 | 4 | _ | |u https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-023-01592-z |
| 856 | 4 | _ | |u https://pub.dzne.de/record/259006/files/DZNE-2023-00715.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://pub.dzne.de/record/259006/files/DZNE-2023-00715.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:259006 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2812261 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)9001596 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)9001378 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)2812127 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)2811691 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)2811347 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 14 |6 P:(DE-2719)2810704 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)2811333 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 17 |6 P:(DE-2719)2810441 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)2812867 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 21 |6 P:(DE-2719)2231621 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 1 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-09 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-09 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2022-11-09 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2022-11-09 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T09:09:14Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T09:09:14Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T09:09:14Z |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ACTA NEUROPATHOL COM : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-26 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ACTA NEUROPATHOL COM : 2022 |d 2023-10-26 |
| 920 | 1 | _ | |0 I:(DE-2719)1110004 |k AG Edbauer |l Cell Biology of Neurodegeneration |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000080 |k AG Zhou |l Adaptive Immunity in Neurodegeneration |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1140013 |k Neuropathology / Brainbank |l Neuropathology / Brainbank |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)1110001 |k AG Herms |l Translational Brain Research |x 3 |
| 920 | 1 | _ | |0 I:(DE-2719)1140004 |k AG Feederle |l Antibody production |x 4 |
| 920 | 1 | _ | |0 I:(DE-2719)1111016 |k Clinical Dementia Research München ; AG Levin |l Clinical Dementia Research München Levin |x 5 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1110004 |
| 980 | _ | _ | |a I:(DE-2719)5000080 |
| 980 | _ | _ | |a I:(DE-2719)1140013 |
| 980 | _ | _ | |a I:(DE-2719)1110001 |
| 980 | _ | _ | |a I:(DE-2719)1140004 |
| 980 | _ | _ | |a I:(DE-2719)1111016 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|